About Eskag Pharma Pvt Ltd
Data last updated: 02 June 2026
Eskag Pharma Pvt Ltd is a private limited company based in Kolkata, West Bengal, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 24 February 1977, the company has been in operation for over 49 years.
Registered with ROC Kolkata under CIN U24234WB1977PTC030897.
Capital: an authorised share capital of ₹1.8 Cr and a paid-up capital of ₹1.68 Cr. It is led by directors Anil Kumar Agarwal and Sunil Kumar Agarwal.
Last AGM: 22 September 2025. Financial statements filed for year ended 31 March 2025. Office: Ag – 112 Unit No – 4 8Th Flooor Baisakhi Sector – Ii Saltlake, Kolkata, West Bengal, India – 700091.
As per the financials filed for FY 2025, the company reported a revenue of ₹82.92 Cr, a growth of 8.07% compared to the previous year.
The company has a workforce of approximately 594 employees as per the latest available data.
The company is associated with 2 brands - Eskag Sanjeevani, Eskag Pharma. As per MCA filings, the company has open charges of ₹126.84 Cr and satisfied charges of ₹35.15 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website eskag.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressAg – 112 Unit No – 4 8Th Flooor Baisakhi Sector – Ii Saltlake, Kolkata, West Bengal, India – 700091
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Eskag Pharma Pvt Ltd
Eskag Pharma Pvt Ltd operates two associated brands: Eskag Sanjeevani and Eskag Pharma. These brands represent Eskag Pharma Pvt Ltd's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Operates as a standalone multi-speciality hospital offering comprehensive medical care. | eskagsanjeevani.com | |
| Manufactures and supplies pharmaceutical products for therapeutic areas like dermatology and gastroenterology. | eskag.in |
Competitors & Alternatives of Eskag Pharma Pvt Ltd
Brands and companies operating in the same space as Eskag Pharma Pvt Ltd include KIMS Hospitals, Fortis Healthcare, Ujala Cygnus and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
KIMS Hospitals
|
Multispeciality secondary and tertiary care is provided by hospital chains. | Secunderabad, India, India | 1999 |
Fortis Healthcare
|
Multi-specialty hospital services are provided across India by Fortis Healthcare. | Gurugram, India, India | 1996 |
Ujala Cygnus
|
A chain of multi-specialty hospitals is operated in India. | Delhi, India, India | 2011 |
Kauvery Hospital
|
Chain of multi-speciality hospitals | Chennai, India, India | 1999 |
Apollo Hospitals
|
Chain of multispecialty hospitals | Chennai, India, India | 1983 |
Jubilant Life Sciences
|
Company offering a suite of R&D and manufacturing services for small molecules and generics | Noida, India, India | 1978 |
Sahyadri Hospitals
|
Multi-speciality hospitals are operated with diverse medical services in India. | Pune, India, India | 1994 |
Akums
|
CDMO focusing on spectrum of dosage forms and therapeutic segments | Delhi, India, India | 2004 |
Narayana Health
|
A chain of multi-specialty hospitals is operated in India. | Bengaluru, India, India | 2000 |
Nectar Lifesciences
|
Cephalosporin APIs and generic formulations are manufactured. | Chandigarh, India, India | 1995 |
Business Activity of Eskag Pharma Pvt Ltd
Eskag Pharma Pvt Ltd operates primarily in the manufacturing sector. The company has 1 registered business activity segment, reflecting its diverse operational portfolio.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| ********* | Manufacturing | ********* | and botanical products Manufacture of pharmaceuticals, medicinal chemical | ********* |
Auditor Details of Eskag Pharma Pvt Ltd
Eskag Pharma Pvt Ltd is audited by MAHENDRA SUBHAS & CO for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| MAHENDRA SUBHAS & CO | blur-value | blur-value | blur-value |
Board of Directors of Eskag Pharma Pvt Ltd
Eskag Pharma Pvt Ltd is currently managed by 2 directors, with 1 former director having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Anil Kumar Agarwal
Also directs:
Upashaya Healthcare Llp, Wbcil (Dahej) Limited, West Bengal Chemical Industries Ltd. and 5 more
|
Director | 11 May 2005 | 21 Years 2 Months | Current |
|
Sunil Kumar Agarwal
Also directs:
Wbcil (Dahej) Limited, West Bengal Chemical Industries Ltd., Bhagirathi Commodities Private Limited and 5 more
|
Director | 13 Jun 1984 | 42 Years 0 Months | Current |
Financials of Eskag Pharma Pvt Ltd FY 2025 filings available
Eskag Pharma Pvt Ltd reported revenue of ₹82.68 Cr (up 8.07% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Eskag Pharma Pvt Ltd
As of FY 2025, Eskag Pharma Pvt Ltd's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Eskag Pharma Pvt Ltd
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Jan 2023 | Standard Chartered Bank | ₹15 Cr | Open |
| 28 Jun 2021 | Standard Chartered Bank | ₹17.57 Cr | Open |
| 21 Jan 2020 | Hdfc Bank Limited | ₹77.58 Cr | Open |
| 29 Dec 2018 | Others | ₹44.5 Lakh | Open |
| 02 Feb 2018 | Hdfc Bank Limited | ₹13.4 Cr | Open |
Total charge records: 12 View all charges
Employees and EPFO Compliance at Eskag Pharma Pvt Ltd
Eskag Pharma Pvt Ltd has a workforce of 594 employees as of Oct 09, 2025.
Employee Count & EPFO Data of Eskag Pharma Pvt Ltd
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Eskag Pharma Pvt Ltd
GSTIN & GST Filing Data of Eskag Pharma Pvt Ltd
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Eskag Pharma Pvt Ltd
Credit Ratings, Legal Cases & Regulatory Alerts of Eskag Pharma Pvt Ltd
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Eskag Pharma Pvt Ltd
MSME Payment Delays by Eskag Pharma Pvt Ltd
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Eskag Pharma Pvt Ltd
Subsidiaries & Group Companies of Eskag Pharma Pvt Ltd
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Eskag Pharma Pvt Ltd with ownership details.
MCA Filings & Documents of Eskag Pharma Pvt Ltd
MCA Filings & Documents of Eskag Pharma Pvt Ltd
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Eskag Pharma Pvt Ltd
Frequently Asked Questions about Eskag Pharma Pvt Ltd
Eskag Pharma Pvt Ltd is an active private limited company in the pharma sector based in Kolkata, West Bengal, India. It was incorporated on 24 February 1977 (49+ years old) and is registered under CIN U24234WB1977PTC030897. The company has 594 employees.
Eskag Pharma Pvt Ltd reported revenue of ₹82.92 Cr for FY 2025 (up 8.07% YoY).
The current directors of Eskag Pharma Pvt Ltd are:
The primary industry of Eskag Pharma Pvt Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Eskag Pharma Pvt Ltd can be reached at the registered office: Ag – 112 Unit No – 4 8Th Flooor Baisakhi Sector – Ii Saltlake, Kolkata, West Bengal, India – 700091, or through the website eskag.in.
The authorised capital is ₹1.8 Cr, and the paid-up capital is ₹1.68 Cr.